Episode 201: Ashley Kalinauskas – How Torigen is Innovating Veterinary Oncology With Immunotherapy
My guest today is Ashley Kalinauskas, CEO of Torigen Pharmaceuticals.
What we discuss with Ashley:
- How her graduate research at Notre Dame led to the founding of Torigen Pharmaceuticals.
- Their approach provides an alternative to chemotherapy by using immunotherapy.
- The company aims to make cancer treatment more accessible and affordable for pet owners.
- Promising results have been seen in aggressive cancers like hemangiosarcoma.
- How Torigen is utilizing digital pathology with the Concentriq platform to improve cancer diagnostics.
- Torigen is conducting research into additional applications, including equine and exotic animal cancers.
- Studying spontaneous cancer in pets provides valuable insights for human oncology research.
- Veterinary immunotherapy advancements have the potential to influence human cancer treatments.
- Immunotherapy is playing an increasingly important role in both veterinary and human medicine.
Links for this episode:
Pathologists’ Assistant Shadowing Network
People of Pathology Podcast:
Responses